VivoSim Labs (NASDAQ:VIVS) Shares Down 0.8% – Here’s Why

VivoSim Labs, Inc. (NASDAQ:VIVS) dropped 0.8% on Wednesday . The stock traded as low as $1.1455 and last traded at $1.18. Approximately 15,132 shares changed hands during trading, a decline of 71% from the average daily volume of 52,297 shares. The stock had previously closed at $1.19.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings downgraded VivoSim Labs from a “sell (d-)” rating to a “sell (e+)” rating in a report on Friday, May 22nd. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, VivoSim Labs presently has an average rating of “Sell”.

VivoSim Labs Stock Performance

The stock’s 50-day simple moving average is $1.41 and its 200 day simple moving average is $1.80. The company has a market capitalization of $3.08 million, a PE ratio of -0.37 and a beta of 1.38.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in VivoSim Labs stock. Two Sigma Investments LP acquired a new stake in VivoSim Labs, Inc. (NASDAQ:VIVS) during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 23,192 shares of the company’s stock, valued at approximately $68,000. Two Sigma Investments LP owned about 0.89% of VivoSim Labs as of its most recent filing with the Securities and Exchange Commission. 8.23% of the stock is currently owned by institutional investors and hedge funds.

About VivoSim Labs

VivoSim Labs, Inc (NASDAQ: VIVS) is a biotechnology company specializing in the development and commercialization of advanced 3D human tissue models for preclinical drug testing and disease modeling. The company’s proprietary organoid platforms and cell-based assays are designed to replicate human physiological environments, enabling more predictive evaluation of drug efficacy, safety, and toxicity before clinical trials. By integrating cutting-edge bioengineering and microfluidics technologies, VivoSim Labs seeks to bridge the gap between traditional cell culture methods and human clinical outcomes.

The company’s product portfolio includes 3D bioprinted tissues, organ-on-a-chip systems, and disease-specific models targeting key therapeutic areas such as oncology, cardiology, and hepatology.